<DOC>
	<DOCNO>NCT02008539</DOCNO>
	<brief_summary>To evaluate safety tolerability MSC_apceth_101 .</brief_summary>
	<brief_title>Treatment Advanced Gastrointestinal Cancer Phase I/II Trial With Modified Autologous MSC_apceth_101</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Patients advance recurrent metastatic gastrointestinal adenocarcinoma . Premature schedule termination standard therapy Progressive disease clinically assess investigator Max . tumour lesion ≤ 5 cm Adequate organ function Ability patient understand character individual consequence clinical trial Age ≥ 18 year Written inform consent must available study specific procedure perform Patients severe heart diseases Clinical significant ischemic disease last 4 week Visit 1 Severe lung disease Symptomatic peritoneal carcinomatosis Symptomatic pleural pericardial effusion Serious uncontrolled acute infection less 3 week Visit 1 Known dependency alcohol drug Patients require corticoid dos Cushing threshold Known liver fibrosis liver cirrhosis Any concomitant severe disease could compromise objective study judgment investigator Female patient pregnant breast feed Participation another clinical trial observation period , respectively , last 4 week prior first IMP dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>